The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but placing funds in companies strongly reliant on off-patent versions presents a challenging picture. Although early earnings were significant, the cessation of patents and the rise of less expensive alternatives have diminished sales. Consequently, a thorough a